Genetic polymorphisms in FAS (CD95) and FAS ligand (CD178) promoters and risk of tobacco-related oral carcinoma: Gene-gene interactions in high-risk Indians

Cancer Investigation

Volumn 31, Issue 1, 2013, Pages 1-6

  Karimi, Mohammad Yahya ^a   Kapoor, Vaishali ^a   Sharma, Suresh Chandra ^a   Das, Satya Narayan ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

FAS; FASL; Indians; Oral cancer; Risk; SNP

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GENE INTERACTION; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ADULT; AGED; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SMOKING;

EID: 84872741300     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2012.743555     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J,Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90
2. Saranath D. Epidemiology and prevention of head and neck cancer: A global view. InContemporary Issues in OralCancer.Oxford: Oxford University Press, 2000
3. Das SN, Khare P, Singh MK, Sharma SC. Fas receptor (CD95 & Fas ligand (CD178) expression in patients with tobaccorelated intraoral squamous cell carcinoma. Indian J Med Res 2011;134:54-60
4. Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995;154:1239-1245
5. Nagata S. Fas ligand and immune evasion. Nat Med 1996;2:1306-1307 (Pubitemid 26401727)
6. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novelmember of the tumor necrosis factor family. Cell 1993;75:1169-1178 (Pubitemid 24006113)
7. ChinnaiyanAM,O'RourkeK, TewariM,DixitVM. FADD, a novel deathdomain-containingprotein, interactswith thedeathdomain of Fas and initiates apoptosis. Cell 1995;81:505-512
8. Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-484 (Pubitemid 40847235)
9. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-582 (Pubitemid 27512871)
10. Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-4330 (Pubitemid 36950998)
11. Bolstad AI,Wargelius A, Nakken B, Haga HJ, Jonsson R. Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome. J Rheumatol 2000;27:2397-2405
12. Wu J,Metz C, Xu X,Abe R,GibsonAW, Edberg JC, Cooke J, Xie F Cooper GS, Kimberly RP. A novel polymorphic CAAT/enhancerbinding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-138 (Pubitemid 36026132)
13. Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030- 1036 (Pubitemid 39162646)
14. Ueda M, Hung Y-C, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M. Fas gene promoter '670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005;98:129-133 (Pubitemid 40826429)
15. Das SN, Baniasadi V, Kapuria V. Association of '308 TNF-alpha promoter polymorphism with type 1 diabetes in North Indians. Int J Immunogenet 2006;33:411-416 (Pubitemid 44760235)
16. Baniasadi V, Narain N, Goswami R, Das SN. Promoter region '318 C/ T and '1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in North Indians. Tissue Antigens 2006;67:383-389
17. Lai H-C, Sytwu H-K, Sun C-A, Yu M-H, Yu C-P, Liu H-S Chang C-C, Chu T-Y. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221-225 (Pubitemid 35461514)
18. Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumors. Oxford:Wiley-Blackwell, 2009
19. Zhang Z, Shi Q, Sturgis EM, Spitz MR, Hong WK, Wei Q. Thymidylate synthase 5'- and 3'-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10:7903-7910 (Pubitemid 39587529)
20. Loro LL, Vintermyr OK, Johannessen AC, Liavaag PG, Jonsson R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999;28:82-87 (Pubitemid 29064509)
21. Shimoyama M, Kanda T, Liu L, Koyama Y, Suda T, Sakai Y Hatakeyama K. Expression of Fas ligand is an early event in colorectal carcinogenesis. J Surg Oncol 2001;76:63-68 (Pubitemid 32128365)
22. Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN Owen-Schaub LB. Fas ligand: A sensor for DNA damage critical in skin cancer etiology. Science 1999;285:898-900 (Pubitemid 29381992)
23. Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3 +regulatory T cells kill autologous CD8+
24. but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469-1480
25. Zhang Z,Wang L-E, Sturgis EM, El-Naggar AK, HongWK, Amos CI, Spitz MR, Wei Q. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:5596-5602 (Pubitemid 44497278)
26. Krippl P, Langsenlehner U, Renner W, Köppel H, Samonigg H. Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1478-1479 (Pubitemid 39429673)
27. ZhuQ,Wang T, Ren J,Hu K, LiuW,WuG. FAS-670A/G polymorphism: A biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. ClinChimActa 2010;411:179-183
28. Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z. The FAS ligand promoter polymorphism, rs763110 ('844C>T), contributes to cancer susceptibility: Evidence from 19 case-control studies. Eur J Hum Genet 2009;17:1294-1303
29. Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas- 1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 2007;27:991-994 (Pubitemid 46587011)
30. Wang L-H, Ting S-C, Chen C-H, Tsai C-C, Lung O, Liu T-C Lee C-W, Wang Y-Y, Tsai C-L, Lin Y-C. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 2010;39:155-161
31. Sung W-W, Wang Y-C, Cheng Y-W, Lee M-C, Yeh K-T, Wang L Wang J, Chen C-Y, Lee H. A polymorphic '844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 2011;17:5991-5999
32. Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312-325
33. Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999;192:48-53 (Pubitemid 29133838)
34. Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest 2001;31:550-553 (Pubitemid 32579393)
35. Crew KD, Gammon MD, Terry MB, Zhang FF, Agarwal M, Eng SM, Sagiv SK, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007;28:2548-2551 (Pubitemid 350238957)